Search research articles
Contact Us
Filters
Showing results (251-260 of 272) with videos related to
Page
of 28
Sort By:
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Tumori
|
June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
BMC Cancer
|
November 26, 2014
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)
Antonio Avallone, Maria Carmela Piccirillo, Paolo Delrio, et al.
The Lancet. Oncology
|
April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
The Journal of Liquid Biopsy
|
January 19, 2026
Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies
Valerio Gristina, Umberto Malapelle, Gennaro Daniele, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer
Glenwood D Goss, Gail E Darling, Virginie Westeel, et al.
Journal of Endocrinological Investigation
|
December 3, 2025
Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review
Francesco Felicetti, Rossella Mazzilli, Stefania Gori, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 272) with videos related to
Sort By:
Page
of 28
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Tumori
|
June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
BMC Cancer
|
November 26, 2014
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)
Antonio Avallone, Maria Carmela Piccirillo, Paolo Delrio, et al.
The Lancet. Oncology
|
April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
The Journal of Liquid Biopsy
|
January 19, 2026
Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies
Valerio Gristina, Umberto Malapelle, Gennaro Daniele, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer
Glenwood D Goss, Gail E Darling, Virginie Westeel, et al.
Journal of Endocrinological Investigation
|
December 3, 2025
Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review
Francesco Felicetti, Rossella Mazzilli, Stefania Gori, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
Page
of 28